Clinical Genomics Appoints Mark Boyle President, In Vitro

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Clinical Genomics Appoints Mark Boyle President, In Vitro Diagnostics

BRIDGEWATER, N.J., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced the appointment of Mark Boyle as President, In Vitro Diagnostics (IVD).

“Mark’s appointment comes at a critical time for our company,” said Lawrence LaPointe, Ph.D., President and CEO of Clinical Genomics. “As we planned for and recently announced the launch of Colvera™, our two-gene test for CRC recurrence monitoring, we recognized the importance of placing a strong leader at the helm of our successful FIT-based screening franchise. With a career spanning more than two decades in the global IVD and life sciences markets, Mark brings a wealth of highly relevant experience that make him uniquely qualified to manage and grow our global FIT testing business.”

Mr. Boyle brings 26 years of commercial experience at leading global IVD and life science companies to his new role at Clinical Genomics. Prior to joining the Company, he served as Vice President at QIAGEN Inc. for nearly five years where he successfully led the company’s global business portfolio in tuberculosis management and helped achieve more than $100 million in revenues. Previously, he was President of Cellestis Inc., where he successfully launched and led the adoption of a screening test for tuberculosis. As a member of the Cellestis executive team, Mr. Boyle played a critical role in the company reaching profitability and was instrumental to its acquisition and successful integration into QIAGEN. He also served as General Manager for the U.K. subsidiary of Diagnostic Systems Laboratories Inc., an IVD manufacturer; and held sales and marketing positions with two Australian biotech start-ups. He holds a B.Sc. in biochemistry and microbiology, and a graduate certificate in management from the University of Adelaide, Australia.

About Colorectal Cancer Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90 percent, but only approximately four out of 10 CRC cases are detected early. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 40 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.

About Clinical Genomics Clinical Genomics is a privately held biotechnology company committed to reducing the impact of colorectal cancer (CRC) through early detection of disease and clinically actionable, evidence-driven recurrence monitoring tools. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred CRC screening InSure® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Building on an established history in the field of CRC screening and diagnosis, Clinical Genomics developed Colvera, a blood-based circulating tumor DNA (ctDNA) test for colorectal cancer based on methylated DNA from two genes, BCAT1 and/or IKZF1.

Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.

For more information, please visit www.colveratest.com  and www.clinicalgenomics.com .

Media Contact: Danielle Lewis, Lazar Partners (212) 843-0211 or (917) 907-4239 dlewis@lazarpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 144

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 157

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 78

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 110

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 150

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading

Top 5 Most Recently Viewed Articles

Vinanz Boosts Bitcoin Mining Operations with New Hardware

Updated Category News Views 160

Vinanz Limited Enhances Bitcoin Mining Capacity Vinanz Limited (US OTCQB: VINZF and AQSE: BTC) has taken a significant step forward in its operations by activating new Bitcoin mining hardware in Nebraska. This move aligns with its broader strategy to expand Bitcoin mining capabilities across North America. Introduction of Advanced Mining Technology The recent deployment...

Continue Reading
Recent Transparency Notification by Nyxoah - Key Insights

Updated Category News Views 202

Understanding Nyxoah's Recent Transparency Notification REGULATED INFORMATION Mont-Saint-Guibert – In alignment with disclosure requirements regarding shareholding changes, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has announced an important transparency notification. Who is Vestal Point Capital? On October 23, Nyxoah disclosed that it received a transparency...

Continue Reading
Mural Oncology Set to Showcase Research at SITC Annual Meeting

Updated Category News Views 48

Mural Oncology Set to Showcase Research at SITC Annual Meeting Mural Oncology plc (NASDAQ: MURA), a pioneering company focused on immuno-oncology, is gearing up for a significant event—the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This important gathering will take place from November 6-10, 2024, in Houston, Texas. Mural Oncology is excited...

Continue Reading
Genmab A/S Announces Share Buyback Progress and Strategy

Updated Category News Views 128

Overview of Genmab's Share Buyback Program Genmab A/S has initiated an impressive share buyback program aimed at enhancing shareholder value. The program, announced on March 25, is designed to repurchase up to 2.2 million shares as part of its strategy to reduce capital and fulfill commitments under the Restricted Stock Unit program. Recent Transactions Under the Buyback...

Continue Reading